TScan Therapeutics, Inc. — fact timeline

TScan Therapeutics, Inc.: Approved amendment to Amended and Restated Certificate of Incorporation to increase authorized shares of voting common stock from 300,000,000 to 600,000,000 (effective 2026-05-20).

“the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 300,000,000 to 600,000,000”

TScan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $1.0 million, net income $28.7 million.

“Revenue: Revenue for the first quarter of 2026 was $1.0 million, compared to $2.2 million for the first quarter of 2025. The decrease was primarily due to timing of research activities pursuant to the Company’s collaboration agreement with Amgen. R&D Expenses: Research and development (R&D) expenses for the first quarter of 2026 were $21.9 million, compared to $29.8 million for the first quarter of 2025. The decrease of $7.9 million was primarily driven by the timing in the purchase of supplies and consumables, as well as savings in connection with the Company’s previously announced strategy to prioritize the clinical development of its heme program. R&D expenses included non-cash stock compensation expense of $1.2 million and $1.7 million for the first quarter of 2026 and 2025, respectively. G&A Expenses: General and administrative (G&A) expenses for the first quarter of 2026 were $8.2 million, compared to $8.6 million for the first quarter of 2025. The decrease of $0.4 million was pr”

TScan Therapeutics, Inc. announced a restructuring with charges of up to approximately $2.3 million affecting the Company (approximately 30% of the Company’s workforce, or 66 roles).

“On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30% of the Company’s workforce, or 66 roles. The Company expects to record a one-time charge of up to approximately $2.3 million during the three months ended December 31, 2025, for severance-related benefits and other costs.”

Garry Nicholson was appointed as Director at TScan Therapeutics, Inc..

“On June 12, 2024, the Board appointed Garry Nicholson to the Board, effective as of the Effective Date.”

Stephen Biggar changed role as Chairman of the Board at TScan Therapeutics, Inc..

“Current member of the Board, Stephen Biggar, M.D., Ph.D., assumed the role of Chairman of the Board, effective as of the Effective Date.”

Timothy Barberich resigned as Chairman of the Board and Director at TScan Therapeutics, Inc..

“On June 12, 2024 (the “Effective Date”), after the conclusion of the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of TScan Therapeutics, Inc. (the “Company”), Timothy Barberich, a member and Chairman of the Board of Directors (the “Board”) of the Company, tendered his resignation from the Board and Chairman position thereof, effective immediately.”

TScan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million.

“• Long-term duration of response data for multiplex therapy anticipated in 2025. First Quarter 2024 Financial Results Revenue: Revenue for the first quarter of 2024 was $0.6 million, compared to $6.8 million for the first quarter of 2023. The decrease was primarily due to the timing of research activities pursuant to the Company’s collaboration agreements.”

TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and TD Securities (USA) LLC valued at $144.7 million (effective 2024-04-16).

“On April 16, 2024, TScan Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 2,472,581 shares (the “Firm Shares”) of its voting common stock, par value $0.0001 per share (the “Voting Common Stock”), at a price to the public of $7.1300 per share, and (b) pre-funded warrants to purchase up to 18,577,419 shares of the Company’s Voting Common Stock (the “Pre-Funded Warrants”), at a price to the public of $7.1299 per warrant with an exercise price of $0.0001 per share (the “Offering”).”

TScan Therapeutics, Inc. reported financial results for the three months and full year ended December 31, 2023.

“TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2023, and provided a business update.”